骨髓增生异常相关突变急性髓系白血病首次缓解期可测量残留病动态对风险分层及指导异基因移植的意义
该回顾性研究分析了188例新发AML-MR患者,根据诱导及1-2疗程巩固化疗后动态MRD分为四组,中位随访36.8个月。第二疗程巩固后持续或复发MRD阳性组3年RFS、OS及累积复发率最差(p<0.001),且为独立风险因素;该组接受allo-SCT的3年OS为70.0% vs 18.2%(p<0.001),交互作用p=0.047。
要点
- 动态MRD可细化新发AML-MR患者风险分层,持续或复发MRD阳性者预后最差
- 第二疗程巩固后持续或复发MRD阳性是RFS和OS的独立危险因素
- 仅该高危亚组从allo-SCT获得显著OS获益(3年OS 70.0% vs 18.2%,p<0.001)
核心结论
- 动态MRD有助于细化风险分层,并识别首次完全缓解期可从allo-SCT获益的新发AML伴MR突变患者。
研究设计与样本
- 回顾性分析188例新发AML-MR患者,依据诱导及1或2疗程巩固化疗后动态MRD分为四个亚组,中位随访36.8个月(范围4.6-73.7)。
主要发现
- 第二疗程巩固后持续或复发MRD阳性组较其他组3年无复发生存、总生存及累积复发率最差(p<0.001)。
- 多因素分析显示该高危组为RFS和OS的独立危险因素。
- allo-SCT的OS获益随MRD风险组呈现显著异质性:D亚组3年OS为接受allo-SCT者70.0% vs 未接受者18.2%(p<0.001),其他组无获益(交互作用p=0.047)。
关键数值与推荐
- 欧洲白血病网2022指南将骨髓增生异常相关基因突变归类为不良遗传学因素。
- 第二疗程巩固后持续或复发MRD阳性组3年RFS、OS及累积复发率较其他组最差(p<0.001)。
- D亚组接受allo-SCT者3年OS 70.0% vs 未接受者18.2%(p<0.001),交互作用p=0.047。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Accurate classification and risk prediction are critical for therapeutic decision-making in patients with acute myeloid leukaemia (AML). Myelodysplasia-related (MR) gene mutations are classified as adverse genetic factors by the European LeukaemiaNet-2022 guidelines. However, their prognostic value in de novo AML remains controversial. This study retrospectively analysed 188 patients with de novo AML-MR, stratifying them into four subgroups based on dynamic measurable residual disease (MRD) after induction, one or two courses of consolidation chemotherapy. The median follow-up was 36.8 months (4.6-73.7). Patients with persistent or recurrent MRD positivity after the second consolidation had the poorest 3-year relapse-free survival (RFS), overall survival (OS) and cumulative incidence of relapse compared to the other groups (p < 0.001). Multivariable analysis identified this high-risk group as an independent risk factor for both RFS and OS. We observed significant heterogeneity of OS benefit from allogeneic stem cell transplantation (allo-SCT) by MRD-risk groups, with substantial OS advantage for patients in subgroup D (3-year OS: allo-SCT 70.0% vs. 18.2% without, p < 0.001) but no benefit for others (p = 0.047 for interaction). This study underscores the importance of dynamic MRD in refining risk stratification and identifying de novo AML patients with MR mutations who would benefit from allo-SCT during the first complete remission.
引用
- Jiang L, Cheng J, Sun J, et al. Dynamics of measurable residual disease for risk stratification and guiding allogeneic transplant in acute myeloid leukaemia patients with myelodysplasia-related mutations in first remission. Br J Haematol. 2024. PMID: 39578220. doi:10.1111/bjh.19917
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。